Elevated Lipoprotein(a) [Lp(a)], a hereditary determinant of atherosclerotic cardiovascular disease (ASCVD) risk, impacts approximately 20–30% of the global populace, with levels surpassing 50 mg/dL. Despite prevailing therapeutic constraints, the significance of Lp(a)] as a prognostic indicator and the advent of targeted interventions have spurred heightened clinical attention. Nevertheless, as guideline-mandated Lp(a) assessments become more prevalent, the clinical response to elevated concentrations, particularly when devoid of established guideline-based treatment mandates, remains an area requiring elucidation.
A recent investigation, presented at the American College of Cardiology, revealed that heightened Lp(a) levels correlated with an expedited and more frequent commencement of prophylactic pharmacotherapy. It should be noted that these response rates were relatively modest within a study cohort characterized by low ASCVD risk, primarily undergoing initial prevention measures.
More precisely, almost 80% of individuals exhibiting elevated Lp(a) concentrations above 50 mg/dL did not initiate lipid-modifying treatments in the absence of other identified ASCVD risk factors. The utilization of medications designed to significantly reduce deleterious LDL cholesterol (such as PCSK9 inhibitors) and the initiation of aspirin therapy were observed even less frequently, indicating a selective rather than a uniform clinical reaction to elevated Lp(a) values. Collectively, these observations suggest that elevated Lp(a)] appears to exert an occasional influence on prescribing habits, a pattern consistent with prior reporting.
Although not presently constituting a sole criterion for initiating statin therapy, elevated Lp(a) is increasingly recognized by medical practitioners as a “risk enhancer,” guiding the implementation of more assertive, yet often inconsistently applied, preventive strategies.
Sheilah A. Bernard MD, corresponding author, associate professor of medicine, Boston University Chobanian & Avedisian School of Medicine
A multicenter retrospective observational cohort study was undertaken by the researchers, assessing the initiation of preventive pharmacotherapy subsequent to Lp(a) measurement in close to 15,000 patients deemed to be at low risk of ASCVD. Within a 90-day window following Lp(a) assessment, the commencement of lipid-modifying therapy was uncommon, yet it occurred with greater frequency among patients presenting with elevated Lp(a)] compared to those with non-elevated levels. The introduction of PCSK9 inhibitor therapy, though rare, was more prevalent in individuals with elevated Lp(a)]. Similarly, aspirin initiation was infrequently observed but demonstrated a higher incidence in those with elevated Lp(a)] levels.
According to the study’s authors, these findings should not be construed as evidence of guideline-adherent prescribing practices. “Current recommendations acknowledge Lp(a)] as a risk-enhancing factor rather than a direct therapeutic target, with no approved medications specifically for Lp(a)] elevation. Our analysis delineates current clinical behavior rather than optimal management,” Bernard, who is also a cardiologist at Boston Medical Center, clarified.
The results of this investigation have also been published online in the American Journal of Preventive Cardiology.
